These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 10229196)

  • 1. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions.
    Smith PD; Crossland S; Parker G; Osin P; Brooks L; Waller J; Philp E; Crompton MR; Gusterson BA; Allday MJ; Crook T
    Oncogene; 1999 Apr; 18(15):2451-9. PubMed ID: 10229196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours.
    Crook T; Brooks LA; Crossland S; Osin P; Barker KT; Waller J; Philp E; Smith PD; Yulug I; Peto J; Parker G; Allday MJ; Crompton MR; Gusterson BA
    Oncogene; 1998 Oct; 17(13):1681-9. PubMed ID: 9796697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 mutations in familial breast cancer: functional aspects.
    Gasco M; Yulug IG; Crook T
    Hum Mutat; 2003 Mar; 21(3):301-6. PubMed ID: 12619116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
    Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
    Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The growth-inhibitory function of p53 is separable from transactivation, apoptosis and suppression of transformation by E1a and Ras.
    Hansen RS; Braithwaite AW
    Oncogene; 1996 Sep; 13(5):995-1007. PubMed ID: 8806689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A; Resnick MA
    Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Progress in molecular genetics of correlating genes of breast cancer].
    Wu Y; Yang L; Wei Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Apr; 19(2):152-5. PubMed ID: 11941595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low expression of bcl-2 in Brca1-associated breast cancers.
    Freneaux P; Stoppa-Lyonnet D; Mouret E; Kambouchner M; Nicolas A; Zafrani B; Vincent-Salomon A; Fourquet A; Magdelenat H; Sastre-Garau X
    Br J Cancer; 2000 Nov; 83(10):1318-22. PubMed ID: 11044356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 physically associates with p53 and stimulates its transcriptional activity.
    Zhang H; Somasundaram K; Peng Y; Tian H; Zhang H; Bi D; Weber BL; El-Deiry WS
    Oncogene; 1998 Apr; 16(13):1713-21. PubMed ID: 9582019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transactivation of the p21 promoter by BRCA1 splice variants in mammary epithelial cells: evidence for both common and distinct activities of wildtype and mutant forms.
    Lu M; Arrick BA
    Oncogene; 2000 Dec; 19(54):6351-60. PubMed ID: 11175350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function.
    Kokontis JM; Wagner AJ; O'Leary M; Liao S; Hay N
    Oncogene; 2001 Feb; 20(6):659-68. PubMed ID: 11313999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
    Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
    J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour p53 mutations exhibit promoter selective dominance over wild type p53.
    Monti P; Campomenosi P; Ciribilli Y; Iannone R; Inga A; Abbondandolo A; Resnick MA; Fronza G
    Oncogene; 2002 Mar; 21(11):1641-8. PubMed ID: 11896595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of apoptosis by the p53-273L (Arg --> Leu) mutant in HSC3 cells without transactivation of p21Waf1/Cip1/Sdi1 and bax.
    Kaneuchi M; Yamashita T; Shindoh M; Segawa K; Takahashi S; Furuta I; Fujimoto S; Fujinaga K
    Mol Carcinog; 1999 Sep; 26(1):44-52. PubMed ID: 10487521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online.
    De Benedetti VM; Radice P; Pasini B; Stagi L; Pensotti V; Mondini P; Manoukian S; Conti A; Spatti G; Rilke F; Pierotti MA
    Hum Mutat; 1998; 12(3):215. PubMed ID: 10660329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation.
    Connor F; Bertwistle D; Mee PJ; Ross GM; Swift S; Grigorieva E; Tybulewicz VL; Ashworth A
    Nat Genet; 1997 Dec; 17(4):423-30. PubMed ID: 9398843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 carries tumor suppressor activity distinct from that of p53 and p21.
    Randrianarison V; Marot D; Foray N; Cabannes J; Méret V; Connault E; Vitrat N; Opolon P; Perricaudet M; Feunteun J
    Cancer Gene Ther; 2001 Oct; 8(10):759-70. PubMed ID: 11687899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation.
    Hakem R; de la Pompa JL; Elia A; Potter J; Mak TW
    Nat Genet; 1997 Jul; 16(3):298-302. PubMed ID: 9207798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers.
    Eiriksdottir G; Barkardottir RB; Agnarsson BA; Johannesdottir G; Olafsdottir K; Egilsson V; Ingvarsson S
    Oncogene; 1998 Jan; 16(1):21-6. PubMed ID: 9467939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.